CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of bulevirtide monotherapy given at 2-mg or 10-mg dose level once daily for treatment of chronic hepatitis delta: Week 48 primary endpoint results from a Phase 3 randomized, multicenter, parallel design study
DOI 10.1055/s-0043-1771821
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH. Wedemeyer, K. Deterding, S. Aleman, M. Brunetto, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, D. Manuilov, V. Suri, Q. An, J. Flaherty, A. Osinusi, J. Schulze zur Wiesch, M. Cornberg, S. Zeuzem, P. Lampertico
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2023
Jahrgang / SeitenJg. 61 · S. e455-e456
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy and safety of bulevirtide monotherapy given at 2-mg or 10-mg dose level once daily for treatment of chronic hepatitis delta: Week 48 primary endpoint results from a Phase 3 randomized, multicenter, parallel design study
Zitieren
Zitierempfehlung
H. Wedemeyer, K. Deterding, S. Aleman, M. Brunetto, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, D. Manuilov, V. Suri, Q. An, J. Flaherty, A. Osinusi, J. Schulze zur Wiesch, M. Cornberg,… (2023) Efficacy and safety of bulevirtide monotherapy given at 2-mg or 10-mg dose level once daily for treatment of chronic hepatitis delta: Week 48 primary endpoint results from a Phase 3 randomized, multicenter, parallel design study. Zeitschrift für Gastroenterologie, 61 (08), e455-e456. https://doi.org/10.1055/s-0043-1771821
Mit CareLit weiterarbeiten